News

Virginia Governor Glenn Youngkin named BIO’s Governor of the Year

Today, the Biotechnology Innovation Organization (BIO) awarded Virginia Governor Glenn Youngkin with its 2024 Governor of the Year Award.

BIO’s annual award honors governors for their leadership and commitment to strengthening biotechnology in their state. For over a decade, the award has recognized governors from across the country and both sides of the aisle.

“Investing in biotechnology is investing in Virginia’s future,” said Governor Glenn Youngkin. “As the Commonwealth’s cutting-edge research triangle and network continues to expand, my administration is determined to remain at the forefront of fostering innovation. I am incredibly humbled to receive this award, and I look forward to further solidifying Virginia’s role as a leader in the life sciences industry.”

“It is my honor to recognize Governor Youngkin with BIO’s 2024 Governor of the Year award for his leadership and support of the life sciences in Virginia,” said BIO President and CEO John F. Crowley. “From advancing innovative economic development initiatives for the bioscience ecosystem to investing in cutting-edge life science facilities across the state, Governor Youngkin has worked tirelessly on public policy solutions to help expand opportunities for researchers, entrepreneurs, and patients in Virginia.”

“Virginia’s $8 billion biotechnology industry is thriving because of the steadfast support of our governmental leaders and regional partnerships,” said John Newby, CEO of the Virginia Biotechnology Association. “We thank Governor Youngkin and his administration for making transformational investments in our ecosystem, and for promoting pro-innovation policies that bring life-improving technologies to patients.”

Read more here.

Recent News

02/20/2025

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

“Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return

02/11/2025

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions,  announced a strategic partnership with BRAINBox Solutions, a leader in multi-modality diagnostics for traumatic brain injury (TBI). This collaboration seeks to develop the first intranasal therapy for mild traumatic brain injury (mTBI) aka concussion, creating a comprehensive trigger-to-treat

02/11/2025

Children’s National and Compremium partner on pediatric medtech innovation

Children’s National Hospital announced a new collaboration with Swiss medical device company Compremium AG to co-develop and commercialize innovative medical technologies designed specifically for pediatric patients. This first-of-its-kind agreement leverages the expertise of Children’s National in pediatric healthcare innovation and Compremium’s non-invasive platform technology for diagnosing pressure-related conditions, accelerating advancements in pediatric medicine. Diagnosing pressure-related